Chester County News and Community Website
WEST CHESTER, PA — Verrica Pharmaceuticals Inc. (Nasdaq: VRCA) has completed enrollment in the first pivotal Phase 3 trial of YCANTH for common warts and passed an interim statistical review …
Verrica Advances Wart Drug Expansion as Phase 3 Trial Fills Read More
MALVERN, PA — Ocugen Inc. (NASDAQ: OCGN) will present 12-month Phase 2 results for its OCU410 gene therapy in geographic atrophy at a scientific meeting in September, putting new clinical …
Malvern Biotech Ocugen to Present New Eye Gene Therapy Data Read More
BLUE BELL, PA — Mitochon Pharmaceuticals received a $1 million clinical trial award from the ALS Association to help fund a 24-week Phase 2 study of its experimental drug MP-101 …
Mitochon Wins $1 Million ALS Award to Advance Phase 2 Trial Read More
WILMINGTON, DE — AstraZeneca and Daiichi Sankyo reported positive Phase III results for ENHERTU in first-line treatment of advanced HER2-mutant non-small cell lung cancer, potentially positioning the drug to move …
AstraZeneca, Daiichi Sankyo Eye Earlier ENHERTU Use Read More
PHOENIXVILLE, PA — PleoPharma Inc. secured a $6.5 million federal grant to advance a Phase 3 trial of its experimental treatment for cannabis withdrawal symptoms, providing three years of funding …
PleoPharma Wins $6.5 Million NIH Grant for Phase 3 Trial Read More
KING OF PRUSSIA, PA — SEED Therapeutics has advanced its experimental cancer treatment into a third dosing cohort in a first-in-human clinical trial, establishing early evidence that the drug degrades …
SEED Advances Cancer Drug as Human Trial Reaches Third Cohort Read More
MALVERN, PA — YPrime was named among Everest Group’s Top 50 Pharmaceutical Technology Providers for 2026, as the clinical-trial technology company expands its use of artificial intelligence to reduce study-development …
YPrime Gains Top 50 Ranking as Clinical Trial AI Expands Read More
PHILADELPHIA, PA — Dispatch Bio has dosed the first patient in a Phase 1 trial of DISP-10 for advanced gastrointestinal cancers, moving its experimental solid-tumor immunotherapy into human testing as …
Dispatch Bio Starts GI Cancer Trial After FDA Fast Track Read More
WAYNE, PA — Aclaris Therapeutics Inc. (Nasdaq: ACRS) received Fast Track designation from the U.S. Food and Drug Administration for modzatinib as a potential treatment for moderate to severe lichen …
FDA Fast Track Status Advances Aclaris Lichen Planus Drug Read More
WASHINGTON, D.C. — The U.S. Department of Veterans Affairs is launching a randomized clinical trial of psilocybin for veterans with treatment-resistant major depressive disorder, including participants with concurrent post-traumatic stress …
VA Launches Psilocybin Trial for Treatment-Resistant Depression Read More